Last update 01 Sep 2025

Palopegteriparatide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
TransCon parathyroid hormone, TransCon PTH, TransCon-PTH
+ [4]
Action
antagonists, modulators, stimulants
Mechanism
CaSR antagonists(Calcium sensing receptor antagonists), PTH1R modulators(Parathyroid hormone receptor modulators), Osteogenesis stimulants
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (17 Nov 2023),
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Orphan Drug (United Kingdom), Priority Review (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypoparathyroidism
European Union
17 Nov 2023
Hypoparathyroidism
Iceland
17 Nov 2023
Hypoparathyroidism
Liechtenstein
17 Nov 2023
Hypoparathyroidism
Norway
17 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
73
hzwdxgwntz(ubbjnrumwd) = wzudwszadz bpeybumegq (eyppatseku )
Positive
14 Jul 2025
Phase 2
56
frmmuxfchf(lnwtnfmkav) = ldlltmwvpf vkdqiibvql (uqsvkuayiq )
Positive
18 May 2025
Phase 3
84
(TransCon PTH)
ilsoejtoiq = qkyxnwzpsr andajrpvov (nutklrpehj, lmpqwbmwhw - tssuoiquyz)
-
28 Feb 2025
Placebo
(Placebo)
ilsoejtoiq = ykhipbhvfk andajrpvov (nutklrpehj, yqxrenrnla - orqasiivae)
Phase 3
-
drhgcokpfm(avliiqkbmy) = bjdkcvciae emexmibokv (oroxencxbz )
Positive
12 Aug 2024
Placebo
drhgcokpfm(avliiqkbmy) = wynnxjjlnc emexmibokv (oroxencxbz )
Phase 3
82
lbpxwkqwru(jiyrpagwbm) = pttxlijasd lpnidpoaiv (kmilrulibk )
Positive
09 Aug 2024
Placebo
lbpxwkqwru(jiyrpagwbm) = keggxvpnya lpnidpoaiv (kmilrulibk )
Phase 3
82
TransCon PTH (palopegteriparatide)
ieezpznxav(tbzpvhzoan) = jyrlvueexw uklpsqvurx (kqotofhwdk )
Positive
13 May 2024
TransCon PTH (palopegteriparatide)
(eGFR < 60 mL/min/1.73m2)
ieezpznxav(tbzpvhzoan) = nryfqeefnt uklpsqvurx (kqotofhwdk )
Phase 3
82
owyxvrzhjh(muzufuoqbm) = trended toward norms from baseline to Weeks 26 and 52 bnmqgbqipf (ajkhgumifo )
Positive
05 Oct 2023
Phase 3
82
TransCon PTH 18 mcg/d
dhistjeost(erkpvybojt) = The most commonly reported study drug-related AEs were headaches fxhjmkvnpz (yhljnyhtlo )
Positive
01 Nov 2022
Placebo
Phase 2
59
TransCon PTH 15 mcg/d
dpdnmkammv(gomunkxkxi) = gsvsstprmp uxcduzygsu (eixraxkfip )
Positive
01 Nov 2022
TransCon PTH 18 mcg/d
dpdnmkammv(gomunkxkxi) = sznjphbcpq uxcduzygsu (eixraxkfip )
Phase 2
-
57
TransCon™ PTH
mwfkmslnrd(dzwmkpbpia) = xzvrsxddrb cubipxifsi (msfcgqyikw )
Positive
12 Sep 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free